Welcome to our dedicated page for Grace Therapeutics news (Ticker: GRCE), a resource for investors and traders seeking the latest updates and insights on Grace Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Grace Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Grace Therapeutics's position in the market.
Grace Therapeutics (NASDAQ: GRCE) announced its participation in the American Society of Health-System Pharmacists (ASHP) mid-year clinical meeting from December 8-12, 2024, in New Orleans. The company will focus on educating health-system pharmacists about unmet needs in aneurysmal subarachnoid hemorrhage (aSAH) treatment and their product GTx-104, a novel injectable nimodipine formulation.
The company expects data readout from their Phase 3 STRIVE-ON trial in Q1 2025. The ASHP represents 60,000 pharmacists and healthcare professionals across various patient care settings. Additionally, Grace recently hosted a virtual KOL event on November 20, 2024, featuring experts discussing aSAH treatment needs.
Grace Therapeutics (NASDAQ: GRCE) reported Q2 fiscal 2025 financial results, highlighting completion of patient enrollment in Phase 3 STRIVE-ON safety trial for GTx-104, their injectable nimodipine formulation for aSAH treatment. The company posted a net loss of $3.4 million ($0.30 per share) compared to $3.3 million last year. R&D expenses increased to $3.0 million from $0.5 million, while G&A expenses rose to $1.9 million. With $15.1 million in cash, the company expects runway into Q2 2026. Grace anticipates STRIVE-ON trial data readout in Q1 2025 and NDA submission in 1H 2025.
Grace Therapeutics (Nasdaq: GRCE) announced a virtual Key Opinion Leader (KOL) event scheduled for November 20, 2024, at 2:00 PM ET. The event will focus on GTx-104, their novel injectable formulation of nimodipine developed for aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening condition.
Featured speakers include Dr. Abhishek Ray from University Hospitals and Dr. Andrew Webb from Massachusetts General Hospital. They will discuss the unmet medical needs and current treatment landscape for aSAH patients. The presentation will be followed by a Q&A session.
FAQ
What is the current stock price of Grace Therapeutics (GRCE)?
What is the market cap of Grace Therapeutics (GRCE)?
